Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)
China
· Delayed Price · Currency is CNY 36.60
-0.35 (-0.95%)
Mar 9, 2026, 3:00 PM CST
Hangzhou Biotest Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Operating Revenue | 448.37 | 519.74 | 435.93 | 1,894 | 1,811 | Upgrade
|
| Other Revenue | - | 39.67 | 6.18 | 7.23 | 7.09 | Upgrade
|
| Revenue | 448.37 | 559.4 | 442.11 | 1,901 | 1,818 | Upgrade
|
| Revenue Growth (YoY) | -19.85% | 26.53% | -76.74% | 4.57% | 110.09% | Upgrade
|
| Cost of Revenue | - | 286.6 | 269.6 | 940.21 | 705.47 | Upgrade
|
| Gross Profit | 448.37 | 272.81 | 172.51 | 960.93 | 1,113 | Upgrade
|
| Selling, General & Admin | - | 85.9 | 79.21 | 86.09 | 69.63 | Upgrade
|
| Research & Development | - | 63.57 | 80.48 | 108.21 | 61.92 | Upgrade
|
| Other Operating Expenses | 398.32 | 7.05 | 4.95 | 19.49 | 16.84 | Upgrade
|
| Operating Expenses | 398.32 | 160.05 | 168.31 | 208.2 | 151.61 | Upgrade
|
| Operating Income | 50.05 | 112.76 | 4.21 | 752.73 | 961 | Upgrade
|
| Interest Expense | - | -0.03 | -0.14 | -0.19 | -0.68 | Upgrade
|
| Interest & Investment Income | - | 57.28 | 76.9 | 51.91 | 15.36 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 11.44 | 13.07 | 111.92 | -15.48 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.85 | -1.92 | -0.59 | -1.1 | -0.87 | Upgrade
|
| EBT Excluding Unusual Items | 49.2 | 179.52 | 93.46 | 915.26 | 959.34 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 0.26 | - | 0.06 | 0.84 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.33 | 0 | - | - | Upgrade
|
| Asset Writedown | - | - | -6.35 | -18.78 | -0 | Upgrade
|
| Other Unusual Items | - | 15.47 | 28.77 | 5.35 | 8.45 | Upgrade
|
| Pretax Income | 49.2 | 194.92 | 115.88 | 901.9 | 968.63 | Upgrade
|
| Income Tax Expense | 2.41 | 28.14 | 10.58 | 128.33 | 132.87 | Upgrade
|
| Earnings From Continuing Operations | 46.8 | 166.78 | 105.3 | 773.56 | 835.76 | Upgrade
|
| Minority Interest in Earnings | - | 2.74 | 1.31 | 0.07 | -2.17 | Upgrade
|
| Net Income | 46.8 | 169.52 | 106.61 | 773.63 | 833.59 | Upgrade
|
| Net Income to Common | 46.8 | 169.52 | 106.61 | 773.63 | 833.59 | Upgrade
|
| Net Income Growth | -72.39% | 59.01% | -86.22% | -7.19% | 91.56% | Upgrade
|
| Shares Outstanding (Basic) | 146 | 147 | 149 | 149 | 121 | Upgrade
|
| Shares Outstanding (Diluted) | 146 | 147 | 149 | 149 | 121 | Upgrade
|
| Shares Change (YoY) | -0.79% | -1.23% | -0.10% | 23.14% | 8.33% | Upgrade
|
| EPS (Basic) | 0.32 | 1.15 | 0.71 | 5.18 | 6.87 | Upgrade
|
| EPS (Diluted) | 0.32 | 1.15 | 0.71 | 5.18 | 6.87 | Upgrade
|
| EPS Growth | -72.17% | 61.00% | -86.21% | -24.64% | 76.84% | Upgrade
|
| Free Cash Flow | - | -116.23 | 74.96 | 524.29 | 707.92 | Upgrade
|
| Free Cash Flow Per Share | - | -0.79 | 0.50 | 3.51 | 5.84 | Upgrade
|
| Dividend Per Share | - | 1.071 | 0.571 | 1.571 | 2.143 | Upgrade
|
| Dividend Growth | - | 87.50% | -63.64% | -26.67% | - | Upgrade
|
| Gross Margin | 100.00% | 48.77% | 39.02% | 50.54% | 61.20% | Upgrade
|
| Operating Margin | 11.16% | 20.16% | 0.95% | 39.59% | 52.86% | Upgrade
|
| Profit Margin | 10.44% | 30.30% | 24.11% | 40.69% | 45.85% | Upgrade
|
| Free Cash Flow Margin | - | -20.78% | 16.95% | 27.58% | 38.94% | Upgrade
|
| EBITDA | 71.32 | 134.03 | 28.88 | 772.63 | 969.2 | Upgrade
|
| EBITDA Margin | 15.91% | 23.96% | 6.53% | 40.64% | 53.31% | Upgrade
|
| D&A For EBITDA | 21.27 | 21.27 | 24.68 | 19.9 | 8.2 | Upgrade
|
| EBIT | 50.05 | 112.76 | 4.21 | 752.73 | 961 | Upgrade
|
| EBIT Margin | 11.16% | 20.16% | 0.95% | 39.59% | 52.86% | Upgrade
|
| Effective Tax Rate | 4.90% | 14.44% | 9.13% | 14.23% | 13.72% | Upgrade
|
| Revenue as Reported | - | 559.4 | 442.11 | 1,901 | 1,818 | Upgrade
|
| Advertising Expenses | - | 2.82 | 4.21 | 3.19 | 1.63 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.